Terry L. Evans
CIK: 0002043317
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
FENNEC PHARMACEUTICALS INC.
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Oct 31, 2026FENC
FENNEC PHARMACEUTICALS INC.
Award(A)Direct168 shares- - Oct 12, 2026FENC
FENNEC PHARMACEUTICALS INC.
Award(A)Direct2.3K shares at avg. $5.53$13K - Sep 30, 2026FENC
FENNEC PHARMACEUTICALS INC.
Award(A)Direct168 shares- - Aug 31, 2026FENC
FENNEC PHARMACEUTICALS INC.
Award(A)Direct168 shares- - Jul 31, 2026FENC
FENNEC PHARMACEUTICALS INC.
Award(A)Direct168 shares- - Jun 30, 2026FENC
FENNEC PHARMACEUTICALS INC.
Award(A)Direct168 shares- - May 31, 2026FENC
FENNEC PHARMACEUTICALS INC.
Award(A)Direct168 shares- - Apr 30, 2026FENC
FENNEC PHARMACEUTICALS INC.
Exercise(M)Direct168 shares- - Mar 31, 2026FENC
FENNEC PHARMACEUTICALS INC.
Exercise(M)Direct18.5K shares- - Mar 31, 2026FENC
FENNEC PHARMACEUTICALS INC.
Award(A)DirectStock Options
120K shares at avg. $5.77- - Mar 31, 2026FENC
FENNEC PHARMACEUTICALS INC.
Exercise(M)Direct171 shares- - Mar 28, 2026FENC
FENNEC PHARMACEUTICALS INC.
Exercise(M)Direct2.1K shares- - Mar 28, 2025FENC
FENNEC PHARMACEUTICALS INC.
Award(A)DirectRestricted Share Unit
10K shares- - Mar 28, 2025FENC
FENNEC PHARMACEUTICALS INC.
Award(A)DirectRestricted Share Unit
10K shares- - Nov 13, 2024FENC
FENNEC PHARMACEUTICALS INC.
Award(A)DirectStock Options
150K shares at avg. $4.23-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 31, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Award(A) | 168 | - | $0 | Direct |
| Oct 12, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Award(A) | 2,326 | $5.53 | $12,863 | Direct |
| Sep 30, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Award(A) | 168 | - | $0 | Direct |
| Aug 31, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Award(A) | 168 | - | $0 | Direct |
| Jul 31, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Award(A) | 168 | - | $0 | Direct |
| Jun 30, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Award(A) | 168 | - | $0 | Direct |
| May 31, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Award(A) | 168 | - | $0 | Direct |
| Apr 30, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Exercise(M) | 168 | - | $0 | Direct |
| Mar 31, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Exercise(M) | 18,456 | - | $0 | Direct |
| Mar 31, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Award(A) Stock Options | 120,000 | $5.77 | - | Direct |
| Mar 31, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Exercise(M) | 171 | - | $0 | Direct |
| Mar 28, 2026 | FENC FENNEC PHARMACEUTICALS INC. | Exercise(M) | 2,052 | - | $0 | Direct |
| Mar 28, 2025 | FENC FENNEC PHARMACEUTICALS INC. | Award(A) Restricted Share Unit | 10,000 | - | - | Direct |
| Mar 28, 2025 | FENC FENNEC PHARMACEUTICALS INC. | Award(A) Restricted Share Unit | 10,000 | - | - | Direct |
| Nov 13, 2024 | FENC FENNEC PHARMACEUTICALS INC. | Award(A) Stock Options | 150,000 | $4.23 | - | Direct |
1-15 of 15 transactions
About Evans Terry L
Evans Terry L (SEC CIK 0002043317) files insider reports with the SEC as Chief Commercial Officer of FENNEC PHARMACEUTICALS INC. (FENC).
Signal8 holds 13 ownership filings by Evans Terry L (1 Form 3, 12 Form 4), filed between Nov 4, 2024 and Nov 2, 2026. Those filings report 15 transactions, from Nov 13, 2024 to Oct 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Evans Terry L's filings is in RESEARCH TRIANGLE PARK, NC.
Recent filings by Evans Terry L
- Oct 31, 2026: Grant or award of FENC shares (Form 4, code A).
- Oct 12, 2026: Grant or award of FENC shares (Form 4, code A).
- Sep 30, 2026: Grant or award of FENC shares (Form 4, code A).
- Aug 31, 2026: Grant or award of FENC shares (Form 4, code A).
- Jul 31, 2026: Grant or award of FENC shares (Form 4, code A).
Other insiders filing for FENNEC PHARMACEUTICALS INC. (FENC)
- Sayad Pierre Sargis, Chief Medical Officer
- Hackman Jeffrey S., Chief Executive Officer
- Cioffi Christiana Marie, Chief Strategy Officer
- Andrade Robert, CHIEF FINANCIAL OFFICER
- Brughera Marco Maria, Director
- Raykov Rosty, Officer